drugset / Trial / NCT02361866

To Evaluate the Effectiveness(Immunogeneicity) and Safety of 'GC1107' Administered Intramuscularly in Healthy Adults

NCT02361866

Phase 3 Completed 376 enrolled Green Cross Corporation
RandomizedParallel-groupTriple-blindPrevention

Summary

The purpose of this study is to evaluate the effectiveness(immunogeneicity) and safety of 'GC1107' administered intramuscularly in healthy Adults.

Timeline

Start
2014-05
Primary completion
2014-09
Completion
2014-10

Drugs

EvaluationDrugModalityDoseRoute
Subject GC1107 Unknown 0.5 ml Intramuscular
Comparator Td vaccine Vaccine 0.5 ml Intramuscular